arrow
S

Sara Merler

university of verona
H指数:12
被引数:738

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Imaging and Clinical Correlates of [177Lu]Lu-PSMA PET-Defined Eligibility in De Novo Metastatic Prostate Cancer

[177Lu]Lu-PSMA PET定义的初诊转移性前列腺癌的影像学及临床相关性

2026-08-130
OA
EMETPRO: a multicentric, international, retrospective analysis evaluating patients with metastatic hormone-sensitive prostate cancer with early progression

EMETPRO:一项多中心、国际性回顾性分析,评估早期进展的转移性激素敏感性前列腺癌患者

2026-05-290
PRE
Predicting Toxicities and Survival Outcomes in De Novo Metastatic Hormone-Sensitive Prostate Cancer Using Clinical Features, Routine Blood Tests and Their Early Variations

基于临床特征、常规血液检查及其早期变化的去势抵抗性激素敏感前列腺癌的毒性和生存结局预测

Cancers
IF4.4
2026-03-030
OAAI
A roadmap for future clinical research in advanced prostate cancer: Findings from the Advanced Prostate Cancer Consensus Conference (APCCC) 2024

未来晚期前列腺癌临床研究的路线图:2024年晚期前列腺癌共识会议(APCCC)的研究结果

2025-11-210
PRE
Interleukin-8 as a potential prognostic biomarker in renal cell carcinoma: a systematic review and meta-analysis

白细胞介素-8作为肾细胞癌潜在预后生物标志物:一项系统评价和荟萃分析

2025-09-010
OAAI
Clinical outcomes of avelumab and pembrolizumab in advanced urothelial cancer: an observational multicenter retro-prospective study on patients undergoing treatment in clinical practice (AVePEm study)
2025-02-210
OAAI
Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study)

接受免疫治疗的晚期肾细胞癌患者的肿瘤微环境分析 (Meet-URO 18研究)

2024-06-120
PRE
Initial results from 2 Phase I studies of NMS-03305293, a selective PARP1 inhibitor
2023-12-012
PRE
Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations
2023-08-018
OA
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study

接受免疫肿瘤学组合治疗晚期肾细胞癌患者的全球真实世界结果: ARON-1研究

2023-06-2721
PRE
First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin

一线avelumab用于不适合顺铂的PD-L1-positive转移性或局部晚期尿路上皮癌患者

2022-11-019
OAAI
Risk of cardiovascular toxicities and hypertension in nonmetastatic castration-resistant prostate cancer patients treated with novel hormonal agents: a systematic review and meta-analysis

接受新型激素药物治疗的非转移性去势抵抗性前列腺癌患者的心血管毒性和高血压风险: 系统评价和荟萃分析

2021-08-3016
PREAI
Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study)
2021-05-1851
OAAI
Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis
Science
IF45.8
2021-01-010
OA
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists
2020-10-1512
OAAI
Immune tumor microenvironment (TME) in correlation with peripheral blood immune biomarkers as prognostic factor in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: The multicentric retrospective Meet-URO 18 study
2020-09-010
OAAI